Tevogen Bio (NASDAQ:TVGN) Given a $4.20 Price Target at Fundamental Research

Fundamental Research set a $4.20 target price on Tevogen Bio (NASDAQ:TVGN) in a report issued on Friday morning, BayStreet.CA reports. The brokerage currently has a buy rating on the stock.

Tevogen Bio Price Performance

Tevogen Bio stock opened at $0.72 on Friday. Tevogen Bio has a one year low of $0.66 and a one year high of $21.09. The stock has a fifty day moving average of $0.90.

Institutional Investors Weigh In On Tevogen Bio

An institutional investor recently bought a new position in Tevogen Bio stock. Portland Global Advisors LLC acquired a new stake in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 5,782,209 shares of the company’s stock, valued at approximately $21,683,000. Tevogen Bio accounts for approximately 3.0% of Portland Global Advisors LLC’s holdings, making the stock its 9th largest position. Portland Global Advisors LLC owned approximately 36.55% of Tevogen Bio as of its most recent SEC filing.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.